ARMO BioSciences' P2P Acquisition

ARMO BioSciences raised a round of funding on May 10, 2018. Investors include Eli Lilly & Co..

ARMO BioSciences is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the bo…

Articles about ARMO BioSciences' P2P Acquisition: